Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-04-01 Epub Date: 2025-01-14 DOI:10.1097/RLU.0000000000005651

Rongxi Wang, Yilin Li, Ziyang Li, Jiarou Wang, Linlin Li, Jialin Xiang, Chenhao Jia, Xingtong Peng, Yu Wang, Wenbin Ma, Li'ao Wang, Wang Jia, Xiaoyuan Chen, Deling Li, Zhaohui Zhu, Jingjing Zhang

{"title":"Gastrin-Releasing Peptide Receptor Targeting PET/CT With 68 Ga-NOTA-RM26 in the Assessment of Glioma and Combined Multiregional Biopsies.","authors":"Rongxi Wang, Yilin Li, Ziyang Li, Jiarou Wang, Linlin Li, Jialin Xiang, Chenhao Jia, Xingtong Peng, Yu Wang, Wenbin Ma, Li'ao Wang, Wang Jia, Xiaoyuan Chen, Deling Li, Zhaohui Zhu, Jingjing Zhang","doi":"10.1097/RLU.0000000000005651","DOIUrl":null,"url":null,"abstract":"Purpose: The aim of this study was to investigate the value of 68 Ga-NOTA-RM26 ( 68 Ga-RM26), a gastrin-releasing peptide receptor-targeting antagonist labeled with the radionuclide 68 Ga, in the diagnosis of high-grade gliomas and in combination with multiregional biopsies using PET/CT.Patients and methods: After institutional review board approval and informed consent, a total of 35 patients with suspected glioma lesions were enrolled in this study. All patients underwent 68 Ga-RM26 PET/CT scans within 2 weeks before surgery.Results: There were 8 grade II gliomas, 6 grade III gliomas, and 18 grade IV gliomas in a total of 32 glioma lesions. 68 Ga-RM26 PET/CT diagnosed 74.4% of lesions (27/32) of all glioma tumor types, and almost all high-grade gliomas were successfully diagnosed (23/24, 95.8%). Among the 9 negative glioma lesions, there were 8 low-grade gliomas (grade II). There was a significantly higher SUV max , SUV mean , and the lesion-to-background ratio (T/B ratio) in high-grade gliomas compared with low-grade gliomas ( P < 0.001). In addition, there was a high correlation between the immunohistochemical staining score of gliomas and parameters (SUV max , SUV mean , and T/B ratio) on 68 Ga-RM26 PET/CT ( P < 0.001), and verified by immunohistochemical staining on multiple-point samples of glioma lesions guided by 68 Ga-RM26 PET/CT.Conclusions: 68 Ga-RM26 could noninvasively diagnose high-grade gliomas and be a promising PET tracer for predicting glioma grading before surgery. This pilot study indicated that the uptake of 68 Ga-RM26 correlates with WHO grade in glioma, and preoperative 68 Ga-RM26 PET/CT may be helpful to guide multiple-point biopsy of gliomas.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":" ","pages":"316-323"},"PeriodicalIF":9.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005651","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/14 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The aim of this study was to investigate the value of 68 Ga-NOTA-RM26 ( 68 Ga-RM26), a gastrin-releasing peptide receptor-targeting antagonist labeled with the radionuclide 68 Ga, in the diagnosis of high-grade gliomas and in combination with multiregional biopsies using PET/CT.

Patients and methods: After institutional review board approval and informed consent, a total of 35 patients with suspected glioma lesions were enrolled in this study. All patients underwent 68 Ga-RM26 PET/CT scans within 2 weeks before surgery.

Results: There were 8 grade II gliomas, 6 grade III gliomas, and 18 grade IV gliomas in a total of 32 glioma lesions. 68 Ga-RM26 PET/CT diagnosed 74.4% of lesions (27/32) of all glioma tumor types, and almost all high-grade gliomas were successfully diagnosed (23/24, 95.8%). Among the 9 negative glioma lesions, there were 8 low-grade gliomas (grade II). There was a significantly higher SUV max , SUV mean , and the lesion-to-background ratio (T/B ratio) in high-grade gliomas compared with low-grade gliomas ( P < 0.001). In addition, there was a high correlation between the immunohistochemical staining score of gliomas and parameters (SUV max , SUV mean , and T/B ratio) on 68 Ga-RM26 PET/CT ( P < 0.001), and verified by immunohistochemical staining on multiple-point samples of glioma lesions guided by 68 Ga-RM26 PET/CT.

Conclusions: 68 Ga-RM26 could noninvasively diagnose high-grade gliomas and be a promising PET tracer for predicting glioma grading before surgery. This pilot study indicated that the uptake of 68 Ga-RM26 correlates with WHO grade in glioma, and preoperative 68 Ga-RM26 PET/CT may be helpful to guide multiple-point biopsy of gliomas.

查看原文本刊更多论文

68Ga-NOTA-RM26靶向胃泌素释放肽受体PET/CT评估胶质瘤及联合多区域活检

目的：本研究旨在探讨用放射性核素68Ga标记的胃泌素释放肽受体靶向拮抗剂68Ga-NOTA-RM26（68Ga-RM26）与PET/CT多区域活检相结合诊断高级别胶质瘤的价值：在获得机构审查委员会批准和知情同意后，共有 35 名疑似胶质瘤病变患者参与了这项研究。所有患者均在手术前两周内接受了 68Ga-RM26 PET/CT 扫描：结果：在32个胶质瘤病灶中，有8个II级胶质瘤、6个III级胶质瘤和18个IV级胶质瘤。68Ga-RM26 PET/CT 诊断出所有胶质瘤类型中 74.4% 的病灶（27/32），几乎所有高级别胶质瘤都被成功诊断（23/24，95.8%）。在9个胶质瘤阴性病灶中，有8个是低级别胶质瘤（II级）。与低级别胶质瘤相比，高级别胶质瘤的SUVmax、SUVmean和病灶与背景比（T/B比）明显更高（P < 0.001）。此外，胶质瘤的免疫组化染色评分与68Ga-RM26 PET/CT的参数（SUVmax、SUVmean和T/B比值）之间存在高度相关性（P＜0.001），68Ga-RM26 PET/CT引导下的胶质瘤病灶多点样本免疫组化染色验证了这一点：68Ga-RM26可以无创诊断高级别胶质瘤，是手术前预测胶质瘤分级的一种有前途的PET示踪剂。这项试点研究表明，68Ga-RM26的摄取与胶质瘤的WHO分级相关，术前68Ga-RM26 PET/CT可能有助于指导胶质瘤的多点活检。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.